CiMaas receives a LIOF grant to optimize feeder cells preparation facilitating expansion of Natural Killer cells
CiMaas’ leading product to fight cancer is Natural Killer (NK) cells. These cells kill tumor cells directly as has been […]
News
News
News
CiMaas receives exclusive option for the use of high affinity antibody structures in immune cells, including CAR-NK and CAR-T cells
By entering into a research collaboration with an option for an exclusive commercial license for its antibody structures (specific directed against
News
Dean Lee joins scientific advisory board of CiMaas
After several years of collaboration, Professor Dr Dean Lee has become a formal member of the scientific advisory board of CiMaas
News
CiMaas to present at Biotech Showcase 2023
CiMaas BV, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary NK cell expansion platform,
News
CiMaas reaches next milestone in NK cell expansion and function
CiMaas successfully expands Natural Killer (NK) cells to clinically relevant numbers using a 2-week protocol. Starting from 200 ml peripheral
News
CiMaas receives Manufacturing Authorisation
As of March 1, 2022, CiMaas is a licensed manufacturer for cell-based products. The company received the manufacturing authorization from
News
CiMaas and consortium receive Health Holland subsidy
CiMaas, together with the Maastricht University Medical Center+ and the University Medical Center Utrecht have received a subsidy of €
News
CiMaas receives RVO innovation credit for DC vaccine clinical trial
Cimaas has received an important stimulus from the Netherlands Enterprise Agency (RVO) for the development of a therapeutic dendritic cell (DC) vaccine against lung cancer.
News
Jolanda de Vries joins scientific advisory board of CiMaas
As of October 1, 2020 esteemed tumor immunologist Prof Dr Jolanda de Vries becomes a member of the scientific advisory
News
Oncologie.nu publishes interview with CEO Gerard Bos
Dutch website Oncologie.nu has interviewed CiMaas’ Gerard Bos on the development of the dendritic cell vaccine for lung cancer.